Zyme Communications Ltd

Our latest newsletter is now live! 📰   This edition is packed with innovative product launches, collaborations, trial updates, and appointments. Not only that, it also marks our one year anniversary of sharing these round-ups – what a great journey it’s been so far!   Be sure to subscribe and visit our website to stay informed about the latest news and developments across the life sciences industry: https://lnkd.in/dzNPNup

Our Founder & CEO Pierre Arsène spoke with the influential lifescience trade publication The Medicine Maker as part of the prediction’s series, “The Multifaceted Future of Pharma”.   For the second piece in the series, Pierre discusses the upcoming clinical translation of extracellular vesicle (EV) science into highly innovative products that could benefit millions of patients in the future.   Pierre comments: “Looking ahead, as technological innovations converge, EVs are well positioned to become one of the key biotech disruptors in the next 10 years.”   Read the article: https://shorturl.at/AToK3 (free subscription required to access it)

Sapio Sciences today announced the expansion of its long-term collaboration with AWS through the integration of AWS Bedrock with the Sapio lab informatics platform. This integration makes advanced generative AI models readily accessible to scientists and researchers within the same secure AWS environment that already powers Sapio's Laboratory Information Management System (LIMS) and Eletronic Lab Notebook (ELN). Leveraging the unique capabilities of Amazon Bedrock in the Sapio lab informatics platform gives customers access to a variety of the latest AI foundational models, including AI21 Labs, Anthropic, and Stability AI. Read more here: https://rb.gy/6ae6ct #AI #GenAI #LabInformatics #NaturalLanguage #LIMS #ELN

The UK Government has announced a new 'Regulatory Innovation Office' (RIO), aiming to speed up access to new technologies by providing a more streamlined route to market. The office will be responsible for working with regulators to update regulations and informing the government of any areas that are holding back innovation for products across four rapidly-growing sectors: ➡ Engineering biology ➡ AI & digital healthcare ➡ Automated technology ➡ Space Read the full announcement: https://bit.ly/4e0razI

VALANX Biotech and Fina BioSolutions LLC today announced the signing of a joint IP and licensing agreement to launch ClickCRM™, a ready-to-conjugate version of CRM₁₉₇, an antigen carrier protein used for making conjugate vaccines. The new products enables the rapid, high-efficiency conjugation of carrier proteins to polysaccharide antigens for the generation of conjugate vaccines, which have improved efficacy against bacterial infections compared with polysaccharide vaccines. Read more here: https://rb.gy/9jt0ig #Vaccines #IP #Commercialisation

Earlier this week, Kadans Science Partner broke ground on its new purpose-built commercial sciences facilities at Merlin Place, Cambridge. The new facilities include CL2 wet labs, dry labs, and office space, and has been designed with the community in mind, with a public café and social spaces. Thank you for inviting us to join partners and contractors at the breaking ground ceremony to learn more about Kadans’ commitment to sustainable development and how the team is addressing the chronic undersupply of laboratory space in the Cambridge cluster. Read more: https://lnkd.in/efnKCKPd

Our team joined Start Codon yesterday for its latest START Programme day: 'Meet the Experts', where our MD, Lorna Cuddon, gave a talk on communications for life science start-ups. We also met with several of the portfolio companies, offering individual advice and discussed current challenges and future opportunities. The day also featured presentations from Taylor Wessing on all things legal, Venner Shipley on IP and Patents, and Triple Chasm on commercialisation, and finally a presentation from AstraZeneca on partnering with pharma as part of a networking session organised by Founders Growth Community. We also had a great time catching up with some of Start Codon's portfolio companies and making new connections – thanks to the Start Codon team and Founders Growth Community for hosting a fantastic event! #StartUps #Communications #Networking #LifeSciences

Sapio Sciences today announced the addition of new Electronic Batch Record (EBR) functionality to Sapio GMP LIMS, launched earlier this year. Designed for laboratories that must comply with GMP, 21 CFR 11, and EU Annex 11 standards, the Sapio GMP LIMS offers flexibility to meet compliance standards in biotechnology, pharmaceuticals, clinical research and diagnostics, food and beverage, chemicals, and environmental testing. The addition of EBR functionality extends Sapio GMP LIMS capabilities to track every aspect of the batch manufacturing process, ensuring batch-level quality control and traceability. Read more here: https://rb.gy/z0gmxk #GMP #LabInformatics #LIMS

⏰ Don't miss out on early bird rates for #BioSeed, only available until 1st November! Secure a spot today to present your company in front of a packed #investor audience, and benefit from a full day of dedicated partnering opportunities to grow your network. Find out more or register: https://bit.ly/3Uh0xzC

With support from Innovate UK's Contracts for Innovation, Newcells Biotech Ltd has developed a 3D retinal model that is transforming drug discovery. This model improves the accuracy of preclinical data and reduces the need for animal testing, making drug development more efficient and reliable. 🧬 Supported by a £1 million award through the 'CRACK IT: Retinal 3D Challenge', the model is advancing safer, more effective eye treatments. It has driven over 50% annual revenue growth and generated more than £5 million in just three years. Newcells is now expanding globally, partnering with companies in the EU, US, Japan, and Taiwan to advance retinal and gene therapy development. Innovate UK's Contracts for Innovation have helped over 100 public sector organisations tackle complex challenges with mutually beneficial funding. Learn more about Newcells' journey: https://ow.ly/V2eO50TQK5u #Innovation #DrugDiscovery #Biotech #RetinalResearch #GeneTherapy #NewcellsBiotec